Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.
Approval Alert | Linvoseltamab in Relapsed/Refractory Multiple Myeloma
Advertisement
Advertisement
Trending on CancerNetwork
1
Mosunetuzumab Treatment Combo Yields Responses in High-Risk MCL
2
Dara-KRd Regimen Displays Prolonged PFS in Newly Diagnosed Multiple Myeloma
3
Giredestrant Combo Significantly Boosts PFS in ER+ Advanced Breast Cancer
4
Optimizing the Timing of Genetic Testing in Advanced Ovarian Cancer
5
